Publication: Performance of a redesigned HIV selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants
Issued Date
2014-01-01
Resource Type
ISSN
1556679X
15566811
15566811
Other identifier(s)
2-s2.0-84896767491
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical and Vaccine Immunology. Vol.21, No.3 (2014), 391-398
Suggested Citation
Oksana Penezina, Neil X. Krueger, Isaac R. Rodriguez-Chavez, Michael P. Busch, John Hural, Jerome H. Kim, Robert J. O'Connell, Eric Hunter, Said Aboud, Keith Higgins, Victor Kovalenko, David Clapham, David Crane, Andrew E. Levin, Supachai Rerks-Ngarm, Punnee Pitisuttithum, Sorachai Nitayaphan, Jaranit Kaewkungwal, Charla Andrews, William Kilembe, Etienne Karita, Susan Allen, Patricia Munseri, Agricola Joachim, Muhammad Bakari, Fred Mhalu, Eric Aris, Charlotta Nilsson, Gunnel Biberfeld, Merlin Robb, Mary Marovich, Eric Sandstrom Performance of a redesigned HIV selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants. Clinical and Vaccine Immunology. Vol.21, No.3 (2014), 391-398. doi:10.1128/CVI.00748-13 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/33513
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Performance of a redesigned HIV selectest enzyme-linked immunosorbent assay optimized to minimize vaccine-induced seropositivity in HIV vaccine trial participants
Author(s)
Oksana Penezina
Neil X. Krueger
Isaac R. Rodriguez-Chavez
Michael P. Busch
John Hural
Jerome H. Kim
Robert J. O'Connell
Eric Hunter
Said Aboud
Keith Higgins
Victor Kovalenko
David Clapham
David Crane
Andrew E. Levin
Supachai Rerks-Ngarm
Punnee Pitisuttithum
Sorachai Nitayaphan
Jaranit Kaewkungwal
Charla Andrews
William Kilembe
Etienne Karita
Susan Allen
Patricia Munseri
Agricola Joachim
Muhammad Bakari
Fred Mhalu
Eric Aris
Charlotta Nilsson
Gunnel Biberfeld
Merlin Robb
Mary Marovich
Eric Sandstrom
Neil X. Krueger
Isaac R. Rodriguez-Chavez
Michael P. Busch
John Hural
Jerome H. Kim
Robert J. O'Connell
Eric Hunter
Said Aboud
Keith Higgins
Victor Kovalenko
David Clapham
David Crane
Andrew E. Levin
Supachai Rerks-Ngarm
Punnee Pitisuttithum
Sorachai Nitayaphan
Jaranit Kaewkungwal
Charla Andrews
William Kilembe
Etienne Karita
Susan Allen
Patricia Munseri
Agricola Joachim
Muhammad Bakari
Fred Mhalu
Eric Aris
Charlotta Nilsson
Gunnel Biberfeld
Merlin Robb
Mary Marovich
Eric Sandstrom
Other Contributor(s)
Immunetics, Inc.
National Institute of Dental and Craniofacial Research
Blood Systems Research Institute
Fred Hutchinson Cancer Research Center
Walter Reed Army Institute of Research
Armed Forces Research Institute of Medical Sciences, Thailand
Emory University
Muhimbili University of Health and Allied Sciences
Global Solutions for Infectious Diseases
Thailand Ministry of Public Health
Mahidol University
Muhimbili National Hospital
Karolinska Institutet
Swedish Institute for Communicable Disease Control
HJF
National Institute of Dental and Craniofacial Research
Blood Systems Research Institute
Fred Hutchinson Cancer Research Center
Walter Reed Army Institute of Research
Armed Forces Research Institute of Medical Sciences, Thailand
Emory University
Muhimbili University of Health and Allied Sciences
Global Solutions for Infectious Diseases
Thailand Ministry of Public Health
Mahidol University
Muhimbili National Hospital
Karolinska Institutet
Swedish Institute for Communicable Disease Control
HJF
Abstract
Vaccine-induced seropositivity (VISP) or seroreactivity (VISR), defined as the reaction of antibodies elicited by HIV vaccines with antigens used in HIV diagnostic immunoassays, can result in reactive assay results for vaccinated but uninfected individuals, with subsequent misclassification of their infection status. The eventual licensure of a vaccine will magnify this issue and calls for the development of mitigating solutions in advance. An immunoassay that discriminates between antibodies elicited by vaccine antigens and those elicited by infection has been developed to address this laboratory testing need. The HIV Selectest is based on consensus and clade-specific HIV peptides that are omitted in many HIV vaccine constructs. The assay was redesigned to enhance performance across worldwide clades and to simplify routine use via a standard kit format. The redesigned assay was evaluated with sera from vaccine trial participants, HIV-infected and uninfected individuals, and healthy controls. The HIV Selectest exhibited specificities of 99.5% with sera from uninfected recipients of 6 different HIV vaccines and 100% with sera from normal donors, while detecting HIV-1 infections, including intercurrent infections, with 95 to 100% sensitivity depending on the clade, with the highest sensitivities for clades A and C. HIV Selectest sensitivity decreased in very early seroconversion specimens, which possibly explains the slightly lower sensitivity observed for asymptomatic blood donors than for clinical HIV cases. Thus, the HIV Selectest provides a new laboratory tool for use in vaccine settings to distinguish the immune response to HIV vaccine antigens from that due to true infection. Copyright © 2014, American Society for Microbiology. All Rights Reserved.